Drug Dev
Advicenne CEO updates on Phase III rare disease program
Advicenne's CEO Luc-André Granier talks to Scrip about the development journey of its Phase III pediatric-friendly product for a rare renal disease and the differences involved when creating a product for use across various age groups. He also discusses the company's recent IPO and his future vision for the business.